Charles River beats quarterly estimates on stable demand for drug development services
- Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients.
- 02/19/2025
|
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 02/17/2025
|
Is Now the Right Time to Hold on to Charles River Stock?
- CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
- 02/14/2025
|
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/12/2025
|
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
- WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.
- 02/11/2025
|
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
- Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
- 02/03/2025
|
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
- CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
- 01/22/2025
|
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.
- 01/21/2025
|
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
- Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO.
- 01/21/2025
|
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
- Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
- 01/17/2025
|
Should You Retain Charles River Stock in Your Portfolio Now?
- CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
- 01/02/2025
|
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
- The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
- 12/17/2024
|
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
- Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
- 12/09/2024
|
CRL Stock to Gain From the Global Biotech Incubator Program Launch
- Charles River's new initiative specifically caters to early-stage biotechnology developers.
- 12/06/2024
|
Charles River Introduces Global Biotech Incubator Program
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offeri.
- 12/05/2024
|
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
- Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
- 11/28/2024
|
Charles River (CRL) International Revenue in Focus: Trends and Expectations
- Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
- 11/11/2024
|
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
- Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David Windley - Jefferies Group LLC Eric Coldwell - Robert W. Baird & Co. Justin Bowers - Deutsche Bank Dan Leonard - UBS Group AG Elizabeth Anderson - Evercore ISI Michael Ryskin - BofA Securities, Inc. Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Chase & Co. Luke Sergott - Barclays Patrick Donnelly - Citigroup Inc. Operator Please stand by, we're about to begin.
- 11/06/2024
|
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
- CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
- 11/06/2024
|
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/06/2024
|
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates
- Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.
- 11/06/2024
|
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
- Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services.
- 11/06/2024
|
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
- Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/30/2024
|
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again
- Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/29/2024
|
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
- Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
- 10/22/2024
|
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
- Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
- 10/18/2024
|
Charles River Launches New Retrogenix® Non-Human Protein Library
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection.
- 10/17/2024
|
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call.
- 10/16/2024
|
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
- Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
- 10/10/2024
|
Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform
- BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution.
- 10/08/2024
|
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
- STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today announced significant progress following a productive meeting with the U.S. Food and Drug Administration (FDA). The company plans to resubmit its New Drug Application (NDA) for Dasynoc in Q4 2024, incorporating feedback from the Complete Response Letter (CRL) issued by FDA in July 2024. If the FDA sets a.
- 09/19/2024
|
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
- Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
- 09/18/2024
|
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
- New Biological Data Released from IRO® Cell Therapy Manufacturing Platform New Biological Data Released from IRO® Cell Therapy Manufacturing Platform
- 09/18/2024
|
CRL Stock May Benefit From New Neuroscience Research Collaboration
- Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
- 09/09/2024
|
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
- Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
- 09/06/2024
|
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
- SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.
- 08/22/2024
|
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
- Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, suggesting there's no viable reinvestment opportunities to grow. The intrinsic worth of the business is $215–$223/share under present conditions, in my opinion, warranting a hold.
- 08/15/2024
|
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023. Our investigation concerns whether the board of directors of Charles River have breached their fiduciary duties to the company.
- 08/13/2024
|
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
- Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
- 08/12/2024
|
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
- Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth projection includes a 3% revenue decline in FY24, with a fair value of $220 per share based on DCF analysis.
- 08/10/2024
|
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
- Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
- 08/07/2024
|
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Transcript
- Charles River Laboratories International Inc (NYSE:CRL ) Q2 2024 Results Conference Call August 7, 2024 9:00 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations Jim Foster - CEO, President & Chairman Flavia Pease - Corporate Executive VP & CFO Conference Call Participants Matt Sykes - Goldman Sachs Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Dave Windley - Jefferies Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Operator Ladies and gentlemen, thank you for standing by, and welcome to Charles River Laboratories Second Quarter 2024 Earnings Conference Call. Just a reminder, this call is being recorded.
- 08/07/2024
|
Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling
- Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.
- 08/07/2024
|
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
- While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/07/2024
|
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
- Charles River Laboratories International Inc CRL reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.
- 08/07/2024
|
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
- Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
- 08/07/2024
|
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
- Charles River Laboratories trimmed its annual forecast on Thursday, as it no longer expects demand for its drug discovery and development services to improve in the second half of the year, sending its shares down 15% in premarket trading.
- 08/07/2024
|
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 08/05/2024
|
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
- Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
- 07/24/2024
|
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules second-quarter 2024 earnings release and conference call for Wednesday, August 7th.
- 07/16/2024
|
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
- SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.
- 07/16/2024
|
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
- Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
- 07/09/2024
|
Charles River to Perform Plasmid Manufacturing for AAVantgarde
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertis.
- 07/08/2024
|
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
- Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
- 07/05/2024
|
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
- Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
- 06/27/2024
|
Charles River (CRL) Inks CDMO Deal With Gates Institutes
- Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
- 06/26/2024
|
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
- ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell.
- 06/25/2024
|
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
- Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
- 06/18/2024
|
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
- SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE:CRL) breached their fiduciary duties to CRL and its shareholders. What can I do?
- 06/17/2024
|
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisor.
- 06/17/2024
|
A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL
- The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to significantly enhance productivity, reduce time spent in drug discovery, and optimize manufacturing processes?
- 06/14/2024
|
Outlook Therapeutics: Worth A Good Strong Look After CRL
- Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to conduct an additional clinical trial for ONS-5010. Its recent Special Protocol Assessment with the FDA sets it up for filing a BLA if the trial is successful in Q4, 2024.
- 06/13/2024
|
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
- SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.
- 06/12/2024
|
Charles River (CRL) Partners to Reduce Animal Research Usage
- Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
- 06/11/2024
|
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces an integrated program, funded by a $1.3 million grant, to develop an in vitro alternative to inhalation toxicology studies.
- 06/11/2024
|
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
- SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.
- 06/06/2024
|
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of a new CRADL® facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.
- 06/06/2024
|
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the launch of its Virtual Control Groups (VCG) initiative with Sanofi to reduce the use of animals in research.
- 06/04/2024
|
Charles River Laboratories to Present at William Blair and Jefferies Conferences
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be avai.
- 06/03/2024
|
Charles River (CRL) Launches Viral Vector Tech Transfer Program
- Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
- 05/31/2024
|
Charles River Laboratories: Fair Valuation Against Fundamentals
- The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratories is a promising investment in this industry, with consistent earnings growth and strong free cash flow margins. CRL's steady Q1 performance and positive outlook for 2024 indicate potential for growth, particularly in its manufacturing solutions division.
- 05/31/2024
|
Reasons to Hold Charles River (CRL) in Your Portfolio Now
- Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
- 05/30/2024
|
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of viral vector contract development and manufacturing organization (CDMO) experience, the Company has designed a methodical program to drive successful, accelerated process transfer to its Maryland-based viral vector center of excellence (CoE) in as little as nine months.
- 05/30/2024
|
Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software
- LONDON--(BUSINESS WIRE)-- #lifesciences--Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River's sample management capabilities. Titian's Mosaic sample management software is already well-established within Charles River's Discovery division, where the company has used the platform for 12 years to support programs from hit-identification to candidate selection. This agreement aims to add significant new capabilities to Charles River's sampl.
- 05/28/2024
|
Charles River (CRL) Banks on RMS Growth Amid Competition
- Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
- 05/24/2024
|
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
- Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
- 05/13/2024
|
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 05/13/2024
|
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
- Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
- 05/09/2024
|
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 05/09/2024
|
The 7 Best Growth Stocks to Buy in May 2024
- It's been a tremendous year for growth stocks. New technologies and increasing consumer adoption in fields such a semiconductors, electric vehicles, and generative AI have led to tremendous gains for growth stocks.
- 05/08/2024
|
Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 05/06/2024
|
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior e.
- 05/02/2024
|
ICLR vs. CRL: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
- 04/29/2024
|
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
- Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
- 04/24/2024
|
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
- 04/22/2024
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
- 04/16/2024
|
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.
- 04/16/2024
|
ICLR or CRL: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
- 04/12/2024
|
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible throug.
- 04/12/2024
|
Charles River (CRL) Forges Collaboration With Ship of Theseus
- Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
- 04/11/2024
|
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex launch Patholytix Foresight, an AI-powered decision support tool for toxicologic pathology.
- 04/11/2024
|
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia's gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure. Ciliopathies are diseases caus.
- 04/09/2024
|
Charles River to Perform Plasmid Production for Ship of Theseus
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River's premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. Sh.
- 04/04/2024
|
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
- WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River's priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet. “The work we do at Char.
- 03/27/2024
|
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
- Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
- 03/26/2024
|
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
- Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
- 03/15/2024
|
Charles River (CRL) Extends Gene Therapy Offering With New Pact
- Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
- 03/15/2024
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
- 03/14/2024
|
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
- SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will present at the Charles River Cell & Gene Therapy Summit at 2:00 p.m. PT, Tuesday, March 19, 2024, in South San Francisco, Calif.
- 03/13/2024
|
The Top 3 Healthcare Stocks to Buy in March 2024
- Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time.
- 03/07/2024
|
Charles River (CRL) Forges Collaboration With Wheeler Bio
- Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
- 02/26/2024
|
Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
- Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
- 02/21/2024
|
Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript
- Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript
- 02/14/2024
|
Charles River (CRL) Q4 Earnings Surpass, Margins Contract
- Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.
- 02/14/2024
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.
- 02/13/2024
|
Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics
- Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
- 02/09/2024
|
Charles River (CRL) to Report Q4 Earnings: What's in Store?
- The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.
- 02/01/2024
|
Charles River (CRL) Launches Animal-Free Endotoxin Test
- Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.
- 01/30/2024
|
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call.
- 01/23/2024
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.
- 01/12/2024
|
Charles River's (CRL) Memphis Site Achieves Crucial Approval
- Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.
- 12/19/2023
|
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
- Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
- 12/13/2023
|
Investing in the Aging Population: 3 Healthcare Stocks to Watch
- In 2016, there were 49 million Americans aged 65 or older. Analysts forecast that will grow to 73 million retirement-age Americans in 2030 and an eye-opening 95 million in the year 2060.
- 12/07/2023
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
- 12/05/2023
|
Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe
- At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
- 11/30/2023
|
Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal
- Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.
- 11/29/2023
|
Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
- Charles River Laboratories provides essential products and services to accelerate research and drug development efforts. The company benefits from competitive advantages thanks to the entry barriers, since its clients usually opt for suppliers with greater scale and reputation. During 2021, the market overvalued the company's shares, but the current price seems attractive and there have been no structural changes in the business.
- 11/26/2023
|
The 3 Most Undervalued Tech Stocks to Buy Now: November 2023
- Looking for undervalued tech stocks to buy now? At first, it might seem challenging as the Nasdaq Composite keeps sprinting toward new highs.
- 11/17/2023
|
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
- Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.
- 11/17/2023
|
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
- Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
- 11/08/2023
|
Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Charles River (CRL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
- 11/06/2023
|
Consulting firm Charles River raises dividend to boost yield above the S&P 500's, while profit and revenue miss expectations
- CRA International Inc. CRAI, +0.09%, the consulting firm also known as Charles River Associates, said Thursday that it raised its quarterly dividend, by 16.7%, to 42 cents a share from 36 cents a share. Shareholders of record on Nov. 28 will be paid the new dividend on Dec. 8.
- 11/02/2023
|
Charles River (CRL) to Report Q3 Earnings: What's in Store?
- Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
- 11/01/2023
|
Why Charles River (CRL) Could Beat Earnings Estimates Again
- Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/24/2023
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.
- 10/10/2023
|
Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar
- Stocks ended the third quarter on a sour note. The Federal Reserve's aggressive posture against inflation combined with soaring interest rates have investors taking defensive measures.
- 10/05/2023
|
Charles River (CRL) Launches LVV-based Gene Therapy Platform
- Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.
- 10/02/2023
|
Charles River (CRL) Opens a RightSource Lab in Stevenage
- Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
- 09/26/2023
|
Here are the 13 stocks Jim Cramer is watching, including Amazon, Oracle and Nike
- Here are some of the tickers on my radar for Friday, Sept. 22, taken directly from my reporter's notebook.
- 09/22/2023
|
Charles River (CRL) Announces Partnership With Related Sciences
- Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.
- 09/15/2023
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.
- 09/06/2023
|
Charles River (CRL) Collaborates With Fondazione Telethon
- Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.
- 08/25/2023
|
Charles River Lab signs joint agreement for protection of crabs used in medical tests
- Charles River Laboratories has signed a joint agreement with four entities to enhance protections in South Carolina for horseshoe crabs and a bird that feeds on their eggs, they said on Thursday.
- 08/24/2023
|
Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed
- Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.
- 08/09/2023
|
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
- Charles River Laboratories (CRL) came out with quarterly earnings of $2.69 per share, beating the Zacks Consensus Estimate of $2.63 per share. This compares to earnings of $2.77 per share a year ago.
- 08/09/2023
|
Is Charles River Laboratories International (CRL) Significantly Undervalued?
- On August 5, 2023, Charles River Laboratories International Inc ( CRL , Financial) experienced a daily gain of 2.66%, with an Earnings Per Share (EPS) of 9.67. This has led to speculation about whether the stock is significantly undervalued.
- 08/05/2023
|
Charles River Laboratories International (CRL): A Significantly Undervalued Gem?
- With a daily gain of 3.46% and an Earnings Per Share (EPS) of 9.67, Charles River Laboratories International Inc ( CRL , Financial) has presented an intriguing question to value investors: Is the stock significantly undervalued? In this article, we will delve into a comprehensive valuation analysis of CRL, offering insightful perspectives to guide your investment decisions.
- 08/04/2023
|
Buy Alert: 3 Healthcare Stocks Nearing Super Attractive Entry Points
- As a prolific cog in the economic machine, the healthcare industry has been a roller coaster ride over the past few years. With the global pandemic, economic slowdown and industry-wide disruptions in play, healthcare stocks took a major hit but are now demonstrating signs of recovery.
- 08/02/2023
|
Charles River (CRL) to Report Q2 Earnings: What's in Store?
- Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.
- 07/31/2023
|
Charles River Laboratories: Very Attractive After The Pullback
- Charles River Laboratories' share price has declined over 50% from its 2021 peak, presenting a potential buying opportunity for investors. The CRO company is facing headwinds from COVID's overhang and funding constraints amid higher interest rates. The long-term outlook of the CRO market remains favorable, and the latest earnings were solid, despite a slowdown in certain segments.
- 07/26/2023
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.
- 07/17/2023
|
3 Cheap Stocks to Buy Before They Bounce Back
- The stock market has indeed had an impressive run in the first half of the year, with the Nasdaq leading the charge and posting record gains. This bullish trend might have left some investors feeling a sense of FOMO (Fear Of Missing Out).
- 07/04/2023
|
Charles River's (CRL) Improved Volume Aids Amid Margin Woe
- Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.
- 06/14/2023
|
3 Long-term Healthcare Stocks to Add to Your Portfolio
- One of the greatest changes in the American landscape going forward will be demographics. The Baby Boomers make up the largest generation in the country's history.
- 06/14/2023
|
Charles River (CRL) Introduces LVV Packaging Plasmids
- Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
- 06/14/2023
|
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
- Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.
- 06/13/2023
|
Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture
- Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.
- 06/09/2023
|
Charles River (CRL) to Build RightSource Lab With New Pact
- Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.
- 06/01/2023
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
- 05/17/2023
|
3 DNA Stocks to Buy for the Synthetic Biology Revolution
- Biology is the study of life. And synthetic biology is the creation of new life for new purposes.
- 05/14/2023
|
Charles River: Strong Earnings Manifest Life Science Megatrends
- In the past year, Charles River (-13.59%) has trailed both the S&P 500 (+4.83%) in addition to the healthcare index, IXHC (+21.81%). This reflects a -44.57% YoY free cash flow decline owing to material reductions in net income from 2021-22.
- 05/11/2023
|
Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed
- Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
- 05/11/2023
|
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
- Charles River Laboratories (CRL) came out with quarterly earnings of $2.78 per share, beating the Zacks Consensus Estimate of $2.59 per share. This compares to earnings of $2.75 per share a year ago.
- 05/11/2023
|
Charles River (CRL) to Report Q1 Earnings: What's in Store?
- Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
- 05/01/2023
|
3 Healthcare Stocks With Huge Growth Potential
- It's been a rocky market for growth stocks over the past 18 months. We've seen a flurry of layoffs and spending cutbacks from leading tech companies.
- 04/24/2023
|
Charles River Associates (CRA) to Host First-Quarter Fiscal 2023 Financial Results Conference Call on May 4
- BOSTON--(BUSINESS WIRE)--CRAI Q1'23 Earnings Advisory
- 04/20/2023
|
Confounded's Complete All-Weather Portfolio Revealed
- Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my main, all-weather portfolio, where roughly 80% of my assets reside.
- 04/01/2023
|
Why Is Charles River (CRL) Down 14.8% Since Last Earnings Report?
- Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
- 03/24/2023
|
Charles River's (CRL) New Cloud Platform Offers Real-Time Data
- Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
- 03/15/2023
|
Charles River (CRL) Advances CDMO Portfolio With Latest Offer
- Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
- 03/14/2023
|
Charles River (CRL) Hurt by NHP Shipment Issue, FX Woes
- The investigation related to the current NHP supply situation is likely to result in study delays in Charles River's (CRL) Safety Assessment business.
- 03/13/2023
|
Charles River Laboratories: Buy This Compounder After The Recent Decline
- Charles River Laboratories' fourth quarter of 2022 was its strongest quarter in the company's history. However, the company's stock dropped ~12% because of challenges the company is facing with non-human primate supply resulting in 2023 guidance coming in below estimates.
- 02/25/2023
|
Charles River Laboratories International, Inc. (CRL) Q4 2022 Earnings Call Transcript
- Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster – Chairman, President and Chief Executive Officer Flavia Pease – Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin – Bank of America Eric Coldwell – Baird Sandy Draper – Guggenheim Elizabeth Anderson – Evercore Patrick Donnelly – Citi Max Smock – William Blair Dan Leonard – Credit Suisse Casey Woodring – JPMorgan Tim Daley – Wells Fargo Dave Windley – Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2022 Earnings Conference Call. This call is being recorded.
- 02/22/2023
|
Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip
- Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
- 02/22/2023
|
Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/22/2023
|
Charles River Dives As Monkey Investigation Hamstrings 2023 Outlook
- Charles River Laboratories announced a shortfall in monkey shipments on Wednesday that weighed on its 2023 outlook, and CRL stock toppled. The post Charles River Dives As Monkey Investigation Hamstrings 2023 Outlook appeared first on Investor's Business Daily.
- 02/22/2023
|
Charles River (CRL) Introduces Novel IgY-Based ELISA Kit
- Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.
- 02/14/2023
|
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
- WILMINGTON, Mass.
- 02/09/2023
|
Charles River (CRL) to Report Q4 Earnings: What's in Store?
- The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
- 01/30/2023
|
Final Trades: Abbvie, Goldman Sachs, Charles River & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 01/20/2023
|
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
- Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
- 01/20/2023
|
Charles River (CRL) to Develop RNA-based Therapy With New Pact
- Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
- 01/19/2023
|
Charles River (CRL) to Advance DNA Programs With New Launch
- Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.
- 01/13/2023
|
Here's Why You Should Retain Charles River (CRL) Stock Now
- Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.
- 12/28/2022
|
Charles River (CRL) Benefits From Price Rise Amid FX Woe
- Charles River's (CRL) RMS growth prospects are high, courtesy of accelerating growth for research model services and research models.
- 12/20/2022
|
Charles River Laboratories International, Inc. (CRL) Q3 2022 Earnings Call Transcript
- Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman, President & CEO Flavia Pease - Corporate EVP & CFO Conference Call Participants Eric Coldwell - Baird Derik De Bruin - Bank of America Sandy Draper - Guggenheim David Windley - Jefferies Elizabeth Anderson - Evercore ISI Patrick Donnelly - Citi Casey Woodring - J.P. Morgan Jacob Johnson - Stephens Justin Bowers - Deutsche Bank John Sourbeer - UBS Dan Leonard - Credit Suisse Christine Rains - William Blair Tejas Savant - Morgan Stanley Timothy Daley - Wells Fargo Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Third Quarter 2022 Earnings Conference Call.
- 11/02/2022
|
Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip
- Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).
- 11/02/2022
|
Why Charles River Laboratories Stock Is Jumping Today
- Investors liked the company's Q3 update.
- 11/02/2022
|
Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 4.78% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2022
|
Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
- Shares of Charles River have been hard hit by operational missteps, but shares are not cheap enough to buy yet. While its safety unit has done very well, its CDMO unit has been slow to build momentum and is unlikely to do so before 2023.
- 10/18/2022
|
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
- 10/11/2022
|
Charles River's (CRL) New Launch to Boost Gene Therapy Workflow
- Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.
- 10/11/2022
|
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
- Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
- 09/21/2022
|
Charles River (CRL) to Support Cure AP-4's Clinical Trials
- Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
- 09/12/2022
|
Charles River Laboratories: A 'Picks And Shovels' Biomedical Play, Now Attractively Priced
- Charles River Labs, or "CRL", provides critical discovery, clinical and safety services to nearly all biotech and pharma companies and has built a hard-earned reputation for quality. With rapid advancements in the medical field occurring more and more frequently, the services the company provides have never been in higher demand.
- 09/10/2022
|
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to Present at September Conferences
- 09/08/2022
|
Why Is Charles River (CRL) Down 10.7% Since Last Earnings Report?
- Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
- 09/02/2022
|
Charles River (CRL) Business Hurt by Macro and FX Headwinds
- In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
- 08/16/2022
|
10 Growth Stocks Analysts Say You'll Be Glad You Bought
- Keeping a list of S&P 500 growth stocks you'd like to own is a good idea. And it might pay off sooner than you think.
- 08/08/2022
|
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q2 2022 Results - Earnings Call Transcript
- Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2022 Earnings Conference Call August 3, 2022 9:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster – Chairman, President and Chief Executive Officer Flavia Pease – Corporate Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin – Bank of America Eric Coldwell – Baird Dave Windley – Jefferies Sandy Draper – Guggenheim Elizabeth Anderson – Evercore Christine Rains – William Blair Justin Bowers – Deutsche Bank Tejas Savant – Morgan Stanley Patrick Donnelly – Citi Jacob Johnson – Stephens Casey Woodring – J.P. Morgan John Sourbeer – UBS Operator Ladies and gentlemen, thank you for standing by and welcome to the Charles River Laboratories' Second Quarter Earnings Conference Call.
- 08/03/2022
|
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
- Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
- 08/03/2022
|
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2022
|
Charles River (CRL) to Report Q2 Earnings: What's in Store?
- The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
- 07/25/2022
|
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
- 07/11/2022
|
Here's Why Investors Should Retain Charles River (CRL) Now
- Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
- 07/05/2022
|
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
- Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
- 06/28/2022
|
Charles River Laboratories: High-Quality Company At A Fair Price
- CRL is a high-quality business that operates quietly and unnoticed in the background. It has consistently grown revenue, earnings and free cash flow over the years.
- 06/22/2022
|
Charles River (CRL) Prospers Internationally Amid FX Headwind
- Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
- 06/21/2022
|
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
- Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
- 06/14/2022
|
Charles River Labs stock slides 6% premarket after company issues profit warning for Q2
- Charles River Laboratories International Inc. shares CRL, +0.89% slid 6% in premarket trade Wednesday, after the drug company issued a profit warning for the second quarter. The company is now expected adjusted per-share earnings to rise in the low-to-mid-single digits from the year-earlier period, down from prior guidance of mid-to-high-single-digit growth.
- 06/08/2022
|
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 06/03/2022
|
Here's Why You Should Retain Charles River (CRL) Stock for Now
- Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
- 05/16/2022
|
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q1 2022 Earnings Call Transcript
- Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2022 Earnings Conference Call May 4, 2022 9:30 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman, President and CEO Flavia Pease - Interim CFO and EVP David Smith - EVP and CFO Conference Call Participants Eric Coldwell - Baird Jacob Johnson - Stephens Elizabeth Anderson - Evercore ISI Dave Windley - Jefferies Casey Woodring - JPMorgan Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/04/2022
|
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
- Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
- 05/04/2022
|
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2022
|
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
- MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
- 05/03/2022
|
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
- Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/27/2022
|
Charles River (CRL) to Report Q1 Earnings: What's in Store?
- Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
- 04/27/2022
|
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
- Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.
- 04/11/2022
|
Here's Why You Should Retain Charles River (CRL) Stock For Now
- Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.
- 04/11/2022
|
Charles River (CRAI) Up on Diversified Business Amid Talent Cost
- Charles River (CRAI) has a diversified business with service offerings across areas of functional expertise, client base and geographical regions.
- 03/25/2022
|
Why Is Charles River (CRL) Down 3.4% Since Last Earnings Report?
- Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
- 03/18/2022
|
Here's Why You Should Retain Charles River (CRL) Stock For Now
- Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.
- 03/09/2022
|
Charles River's (CRAI) Q4 Earnings Beat Estimates, Decline Y/Y
- Charles River's (CRAI) fourth-quarter 2021 revenues improve year over year.
- 03/04/2022
|
Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish
- The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
- 02/22/2022
|
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q4 2021 Results - Earnings Call Transcript
- Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q4 2021 Results - Earnings Call Transcript
- 02/16/2022
|
Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up
- Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.
- 02/16/2022
|
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/16/2022
|
Land on 5 Winning Stocks With the Overlooked Rising P/E Trick
- Stocks with rising P/E often proves to be an intriguing investing idea.
- 02/15/2022
|
Charles River (CRL) to Report Q4 Earnings: What's in Store?
- The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.
- 02/11/2022
|
Is Charles River (CRL) a Solid Growth Stock? 3 Reasons to Think " Yes "
- Charles River (CRL) could produce exceptional returns because of its solid growth attributes.
- 02/04/2022
|
Charles River Laboratories: Healthcare's Research Essential Resource
- The whole Covid-19 pandemic has been a world-wide lesson in the need to be resourceful about the care of personal-life healthcare. Being prepared means the human race needs to anticipate how to deal with what may come to attack us without much warning. Fortunately, the medical profession anticipates.
- 01/22/2022
|
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
- 01/20/2022
|
3 Reasons Why Charles River (CRL) Is a Great Growth Stock
- Charles River (CRL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 01/19/2022
|
Charles River (CRAI) Announces Name of New VP in Oakland
- Charles River (CRAI) welcomes Elizabeth Bailey to the position of vice president of its Antitrust & Competition Economics Practice in Oakland.
- 01/12/2022
|
Charles River (CRAI) Hires New Forensic Services Practice VP
- Charles River (CRAI) welcomes Peggy Daley to the position of vice president its Energy Practice.
- 01/07/2022
|
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to present at J.P. Morgan Healthcare Conference
- 01/06/2022
|
5 Reasons Why You Should Invest in Charles River (CRAI) Stock
- Charles River (CRAI) rides on its strong global presence, business diversification and an excellent professional team.
- 01/03/2022
|
Here's Why You Should Retain Charles River (CRL) Stock for Now
- Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.
- 12/15/2021
|
Why Charles River (CRAI) Could Be an Impressive Growth Stock
- If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Charles River (CRAI).
- 11/30/2021
|
Charles River (CRAI) Stock Up 106% Year to Date: Here's Why
- Charles River (CRAI) stock has been benefiting from consecutive better-than-expected top- and bottom-line performances, and shareholder-friendly moves.
- 11/24/2021
|
Low Debt Aids Charles River (CRAI) Amid High Talent Cost
- Strong balance sheet and measures to drive shareholders' value boost Charles River (CRAI).
- 11/17/2021
|
Charles River (CRAI) Q3 Earnings Beat, '21 Revenue View Down
- Charles River's (CRAI) third-quarter 2021 earnings and revenues improve year over year.
- 11/10/2021
|
Why Charles River Laboratories International Shares Dropped 16.7% This Week
- The company's stock dropped nearly $75 a share over the course of the week, rattling investors.
- 11/04/2021
|
Charles River Posts Mixed Q3 Earnings; Narrows FY21 EPS Guidance
- Charles River Laboratories International Inc (NYSE: CRL) Q3 sales increased 20.5% Y/Y to $895.9 million, missing the consensus of $903.20 million. Acquisitions contributed 5.9% to consolidated third-quarter revenue growth.
- 11/03/2021
|
Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up
- Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.
- 11/03/2021
|
Charles River Laboratories International, Inc.'s (CRL) CEO Jim Foster on Q3 2021 Results - Earnings Call Transcript
- Charles River Laboratories International, Inc.'s (CRL) CEO Jim Foster on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Charles River Laboratories (CRL) Q3 Earnings Top Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 5.06% and -1.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2021
|
Charles River (CRL) to Report Q3 Earnings: What's in the Cards?
- Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).
- 10/28/2021
|
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/27/2021
|
Charles River Laboratories: Expensive, But Will It Ever Get Cheap?
- Charles River Laboratories has come off its recent highs, but that doesn't make the company cheap.CRL is trading at about 30-33 times its anticipated 2021 free cash flow result.
- 10/22/2021
|
Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #HealthcareCollabReport--Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) today announced the formation of a strategic partnership to provide clients access to ATEM's cryo-electron microscopy (cryo-EM) service solutions. Cryo-EM is a technique that determines the 3D structures of proteins and is utilized to identify how proteins function, how they malfunction in disease and the most effective way to target them with therapies. ATEM's lea
- 10/18/2021
|
Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #3Q2021--Charles River Laboratories schedules Third-Quarter 2021 earnings release and conference call
- 10/13/2021
|
Charles River Laboratories Announces Two Divestitures
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announces two divestitures.
- 10/12/2021
|
Charles River (CRAI) Stock Up 106.1% Year to Date: Here's Why
- Consecutive better-than-expected top- and bottom-line performances, and an encouraging 2021 guidance have been aiding Charles River (CRAI) stock.
- 10/06/2021
|
Here's Why You Should Invest in Charles River (CRL) Now
- Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
- 09/14/2021
|
6 Reasons Why You Should Bet on Charles River (CRAI) Stock
- Business diversification and investor-friendly moves aid Charles River (CRAI) stock.
- 09/07/2021
|
Why Charles River (CRAI) Stock Might be a Great Pick
- Charles River (CRAI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 09/03/2021
|
These Top Stocks Are Leading The S&P 500 To New Highs In 2021
- Shares of vaccine-maker Moderna have skyrocketed more than 270% this year.
- 09/02/2021
|
You Won't Believe the Risk This Healthcare Company Faces
- It's older than the dinosaurs.
- 08/21/2021
|
Charles River (CRL) at a 52-Week High: What's Driving It?
- Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
- 08/19/2021
|
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q2 2021 Results - Earnings Call Transcript
- Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
- Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
- 08/04/2021
|
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
Recap: Charles River Q2 Earnings
- Shares of Charles River (NYSE:CRL) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 65.19% year over year to $2.61, which beat the estimate of $2.38.
- 08/04/2021
|
Reasons to Retain Charles River (CRAI) in Your Portfolio
- Charles River (CRAI) has a diversified business with service offerings across areas of functional expertise, client base and geographical regions.
- 07/09/2021
|
10 Top-Ranked Stocks Powering S&P 500 ETF
- The S&P 500 has been outperforming this year due to the strength in value and cyclical stocks, which were battered last year in the pandemic.
- 07/08/2021
|
What's Next For Charles River Laboratories Stock After A 13% Rise Last Month?
- The stock price of Charles River Laboratories, a company that offers clinical laboratory, gene therapy, and cell therapy services for the pharmaceuticals industry, has seen a 13% rise over the last twenty-one trading days. The company recently completed the acquisition of Vigene Biosciences.
- 07/07/2021
|
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
- The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.
- 06/30/2021
|
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
- Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 06/22/2021
|
Charles River Laboratories: Stick With What Has Been Working
- Charles River's stock has significantly outperformed the S&P 500 over the last 1-,3- and 5-year periods. Better yet, Charles River is well-positioned for 2021 and beyond, as I believe the future for this company looks even brighter the further you are willing to look out.
- 06/21/2021
|
Charles River Laboratories to Host Virtual Investor Day
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #investorday--Charles River Laboratories to Host Virtual Investor Day
- 05/26/2021
|
Charles River Acquires Viral Vector Player For $350M
- Contract researcher Charles River Laboratories International Inc (NYSE: CRL) will dole out $292.5 million for gene therapy CDMO Vigene Biosciences with the possibility for an additional $57.5 million in performance-based payments. The deal will close by early Q3.
- 05/17/2021
|
Charles River (CRAI) Beats on Q1 Earnings, Ups '21 Guidance
- Charles River's (CRAI) first-quarter 2021 earnings and revenues improve year over year.
- 05/12/2021
|
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q1 2021 Results - Earnings Call Transcript
- Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q1 2021 Results - Earnings Call Transcript
- 05/04/2021
|
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2021
|
Charles River Laboratories Announces First-Quarter 2021 Results
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces First-Quarter 2021 Results
- 05/04/2021
|
Charles River Laboratories International Inc (CRL) Corporate Executive VP & CFO David Ross.
- Corporate Executive VP & CFO of Charles River Laboratories International Inc (30-Year Financial, Insider Trades) David Ross Smith (insider trades) sold 2,000 shares of CRL on 04/15/2021 at an average price of $320 a share. The total sale was $640,000.
- 04/16/2021
|
Royce International Premier Fund Buys New Work SE, Learning Technologies Group PLC, NICE.
- Investment company Royce International Premier Fund (Current Portfolio) buys New Work SE, Learning Technologies Group PLC, NICE Information Service Co, discoverIE Group PLC, OBIC Business Consultants Co, sells TGS-NOPEC Geophysical Co ASA, Bossard Holding AG, Cosel Co, IRESS, Lagercrantz Group AB during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Royce International Premier Fund. As of 2021Q1, Royce International Premier Fund owns 61 stocks with a total value of $1.1 billion.
- 04/16/2021
|
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
- WILMINGTON, Mass. & MONTREAL--(BUSINESS WIRE)---- $CRL #Biopharma--Charles River and Valence Discovery announce strategic partnership to provide clients access to AI-enabled drug design.
- 04/06/2021
|
Charles River Laboratories Completes the Acquisition of Cognate BioServices
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River Laboratories completes the acquisition of Cognate BioServices.
- 03/29/2021
|
Charles River Laboratories Announces Closing of Senior Notes Offering
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announced that it has closed its previously announced offering of $1 billion of senior notes
- 03/23/2021
|
ETF Strategies to Hedge Against Inflation
- Here are some ways to protect your portfolio from rising inflation.
- 03/11/2021
|
Charles River Laboratories Prices $1 Billion of Senior Notes
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #bondoffering--Charles River Laboratories prices $1 billion of senior notes
- 03/09/2021
|
Charles River Laboratories Announces Planned Offering of $1 Billion of Senior Notes
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #bondoffering--Charles River Laboratories announces planned offering of $1 billion of senior notes
- 03/08/2021
|
Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Today, Charles River announced a partnership with Kibur Medical to offer exclusive access to its IMD for in vivo preclincal oncology studies.
- 02/25/2021
|
Charles River - Powering Along
- Charles Rivers has done well during the pandemic as the pain was short-lived. While it is not a prime beneficiary of Covid-19, the company continues to help its clients progress their pipelines.
- 02/21/2021
|
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q4 2020 Results - Earnings Call Transcript
- Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q4 2020 Results - Earnings Call Transcript
- 02/17/2021
|
Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/17/2021
|
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Fourth-quarter and Full-year 2020 Results and Provides 2021 Guidance
- 02/17/2021
|
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to acquire Cognate Bioservices
- 02/17/2021
|
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
- Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/10/2021
|
Algernon Pharmaceuticals inks deal with Charles River Laboratories for preclinical work on DMT for stroke
- Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), the drug repurposing company, said pre-clinical studies on the psychedelic compound DMT to treat stroke will be carried out at the Charles River research facility in Finland. The company has inked a deal with lab services firm Charles River Laboratories for research studies of AP-188, or DMT, it told investors.
- 02/08/2021
|
Why Charles River (CRL) Could Beat Earnings Estimates Again
- Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/29/2021
|
Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening
- WILMINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River today announced that it has entered into a strategic partnership with Cypre, Inc. to expand in vitro testing services.
- 01/28/2021
|
Charles River Laboratories Schedules Fourth-Quarter 2020 Earnings and 2021 Guidance Release and Conference Call
- WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories schedules fourth-quarter 2020 earnings and 2021 guidance release and conference call.
- 01/20/2021
|
4 Winners Highlight Top Jefferies Growth Stocks to Buy in 2021
- Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.
- 01/11/2021
|
Charles River Labs: And The Beat Goes On
- Charles River reported Q3 2020 results that beat the top- and bottom-line estimates. Moreover, the company has beat analysts' earnings estimates in each of the last eight quarters. Charles River appears to be well-positioned for 2021 and beyond, which also factors in the anticipated near-term COVID headwinds.
- 11/06/2020
|
Charles River Laboratories International, Inc.'s (CRL) CEO James Foster On Q3 2020 Results - Quick Version Earnings Call Transcript
- Charles River Laboratories International, Inc.'s (CRL) CEO James Foster On Q3 2020 Results - Quick Version Earnings Call Transcript
- 10/29/2020
|
Were Hedge Funds Right About Crowding Into Charles River Laboratories (CRL)?
- Is Charles River Laboratories International Inc. (NYSE:CRL) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
- 10/27/2020
|
Plan to retrieve Titanic radio spurs debate on human remains
- A company’s plan to retrieve the Titanic’s radio has sparked a debate over whether the famous shipwreck still holds human remains.
- 10/18/2020
|
Plan To Retrieve Titanic Radio Spurs Debate On Human Remains
- Some 1,500 people died in the 1912 wreck, but how should those victims be honored?
- 10/18/2020
|
Plan to remove radio from wreck of Titanic sparks debate about human remains
- People have been diving to the Titanic's wreck for 35 years. No one has found human remains, according to the company that owns the salvage rights.
- 10/18/2020
|
Plan to retrieve Titanic radio spurs debate on human remains
- NORFOLK, Va. (AP) — People have been diving to the Titanic's wreck for 35 years. No one has found human remains, according to the company that owns the salvage rights. But the company’s plan to retrieve the ship’s iconic radio equipment has sparked a debate: Could the world’s most famous shipwreck still hold remains of passengers and crew who died a century ago? Lawyers for the U.S. government have raised that question in an ongoing court battle to block the planned expedition. They cite archaeologists who say remains could still be there. And they say the company fails to consider the prospect in its dive plan. “Fifteen hundred people died in that wreck,” said Paul Johnston, curator of maritime history at the Smithsonian’s National Museum of American History. “You can’t possibly tell me that some human remains aren’t buried deep somewhere where there are no currents.” The company, RMS Titanic Inc., wants to exhibit the ship's Marconi wireless telegraph machine. It broadcast the sinking ocean liner's distress calls and helped save about 700 people in lifeboats. Retrieving the equipment would require an unmanned submersible to slip through a skylight or cut into a heavily corroded roof on the ship's deck. A suction dredge would remove loose silt, while manipulator arms could cut electrical cords. RMS Titanic Inc. says human remains likely would've been noticed after roughly 200 dives. “It’s not like taking a shovel to Gettysburg,” said David Gallo, an oceanographer and company adviser. “And there’s an unwritten rule that, should we see human remains, we turn off the cameras and decide what to do next.” The dispute stems from a larger debate over how the Titanic's victims should be honored, and whether an expedition should be allowed...
- 10/18/2020
|
Are there still human remains in Titanic wreckage?
- People have been diving to the Titanic’s wreck for 35 years. No one has found human remains, according to the company that owns the salvage rights.
- 10/18/2020
|
Plan to retrieve Titanic radio spurs debate on human remains
- A company’s plan to retrieve the Titanic’s radio has sparked a debate over whether the famous shipwreck still holds human remains
- 10/18/2020
|
Plan to retrieve Titanic radio spurs debate on human remains
- A plan to retrieve the Titanic's iconic radio equipment has sparked a debate: Could the world's most famous shipwreck still hold remains of passengers and crew who died a century ago?
- 10/18/2020
|
Plan to retrieve Titanic radio spurs debate on human remains
- NORFOLK, Va. (AP) - People have been diving to the Titanic's wreck for 35 years. No one has found human remains, according to the company that owns the salvage rights.
But the company's plan to retrieve the ship's iconic radio equipment has sparked a debate: Could the world's most famous shipwreck still hold remains of passengers and crew who died a century ago?
Lawyers for the U.S. government have raised that question in an ongoing court battle to block the planned expedition. They cite archaeologists who say remains could still be there. And they say the company fails to consider the prospect in its dive plan.
"Fifteen hundred people died in that wreck," said Paul Johnston, curator of maritime history at the Smithsonian's National Museum of American History. "You can't possibly tell me that some human remains aren't buried deep somewhere where there are no currents."
The company, RMS Titanic Inc., wants to exhibit the ship's Marconi wireless telegraph machine. It broadcast the sinking ocean liner's distress calls and helped save about 700 people in lifeboats.
Retrieving the equipment would require an unmanned submersible to slip through a skylight or cut into a heavily corroded roof on the ship's deck. A suction dredge would remove loose silt, while manipulator arms could cut electrical cords.
RMS Titanic Inc. says human remains likely would've been noticed after roughly 200 dives.
"It's not like taking a shovel to Gettysburg," said David Gallo, an oceanographer and company adviser. "And there's an unwritten rule that, should we see human remains, we turn off the cameras and decide what to do next."
The dispute stems from a larger debate over how the Titanic's victims should be honored, and whether an expedition should be allowed...
- 10/18/2020
|
Plan to retrieve Titanic radio spurs debate on human remains
- NORFOLK, Va. (AP) — People have been diving to the Titanic's wreck for 35 years. No one has found human remains, according to the company that owns the salvage rights. But the company’s...
- 10/18/2020
|
Cyprus getting to grips with Cybersecurity - Financial Mirror
- The Digital Security Authority (DSA) is bolstering efforts to enhance cybersecurity in Cyprus by addressing risks to essential services while creating a safer environment for investors and businesses. Recent comments by high ranking state officials have put the spotlight on cybersecurity gaps in crucial state services such as ministries, ports, water, and electricity distribution networks.
- 10/03/2020
|
Crisis Management Software Market- Roadmap for Recovery from COVID-19 | Increasing Spread Of Coronavirus Disease Globally to Boost the Market Growth | Technavio
- The Global Crisis Management Software Market will grow by USD 9.35 bn during 2020-2024
- 09/21/2020
|
Marxist memes for TikTok teens: can the internet radicalize teenagers for the left? | Joshua Citarella
- I witness horror stories of social media algorithms turning young people into extremists. But why cede this space to the far right?
- 09/12/2020
|
RMS Brewing Solutions Launches MicroMill | Brewbound
- When it comes to producing the highest quality milling and grain handling products, the craft beer industry knows to trust RMS Brewing Solutions.
- 09/10/2020
|
Charles River Laboratories: Strong Results But Not Out Of The Woods Just Yet
- Charles River reported Q2 2020 results that beat the top and bottom line estimates. However, the company's research business contended with strong headwinds again this quarter.
- 08/16/2020
|
World's First Development and Demonstration of a Quantum Cryptographic Communication Technology Applied System for Genomic Medicine
- Toshiba Corporation (TOKYO: 6502), Tohoku University Tohoku Medical Megabank Organization (ToMMo) and Tohoku University Hospital have demonstrated that quantum cryptographic communications technology can provide genomic medicine with a safe, completely secure data management environment. This was achieved by (1) developing a system which applies quantum cryptographic communications technology to clinical sequencing, and (2) using that system to safely transmit cancer genome analysis data (exome sequence (Note 1) data), via online expert panel attended by physicians and other experts to analyze the sequenced data (Figure 1). This is the world's first development and demonstration of a system using quantum cryptographic communication technology in the field of genomic medicine (Note 2).
- 08/07/2020
|
Charles River Laboratories International Inc (CRL) Q2 2020 Earnings Call Transcript
- CRL earnings call for the period ending June 30, 2020.
- 08/05/2020
|
Charles River Laboratories (CRL) Q2 Earnings and Revenues Beat Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2020
|
Charles River: Q2 Earnings Insights
- Shares of Charles River (NYSE:CRL) moved higher by 0.1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 3.07% year over year to $1.58, which beat the estimate of $1.26.Revenue of $682,584,000 up by 3.80% year over year, which beat the estimate of $641,630,000.Outlook The upcoming fiscal year's EPS expected to be between $7.05 and $7.35.The upcoming fiscal year's revenue expected to be between $2,817,575,000 and $2,857,000,000.Details Of The Call Date: Aug 05, 2020View more earnings on CRLTime: 09:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/4xv2t4mzRecent Stock Performance 52-week high: $208.4452-week low: $95.58Price action over last quarter: Up 27.80%Company Profile Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday * Stocks That Hit 52-Week Highs On Tuesday * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/05/2020
|
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Could Be 34% Above Their Intrinsic Value Estimate
- Today we will run through one way of estimating the intrinsic value of Charles River Laboratories International, Inc...
- 08/05/2020
|
Charles River Laboratories Announces Second-Quarter 2020 Results
- Charles River Laboratories Announces Second-Quarter 2020 Results
- 08/05/2020
|
Agilent Technologies At Upper End Of Buy Range With Earnings Due
- To build your earnings season watch list, look for stocks in or near a potential buy range ahead of their next report. One company that fits that bill is Agilent Technologies (A). It's expected to report on Aug. 18. The stock is approximately 5% above a 93.14 buy point from a first-stage flat base. Buying a stock just ahead of...
- 08/04/2020
|
Luminex Scores Relative Strength Rating Upgrade
- Luminex saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 89 to 92. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. Luminex is within a buying range after clearing a 38.23 entry in a cup with handle.
- 08/04/2020
|
Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More
- The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.
- 08/04/2020
|
Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?
- Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/04/2020
|
Nothing direct about DSA selection
- Ahead of this year’s National School Games (NSG), rugby player Jared Khuan was raring to get on the field with his Bukit Batok Secondary School team after he was handed the captain’s armband.. Read more at straitstimes.com.
- 08/02/2020
|
School Sports: Direct School Admission exercise goes online amid Covid-19 pandemic
- SINGAPORE - Ahead of this year's National School Games (NSG), rugby player Jared Khuan was raring to get out on the field with his Bukit Batok Secondary School team after he was handed the captain's armband.. Read more at straitstimes.com.
- 08/02/2020
|
Should Investors Buy the Dip in Charles River Laboratories (CRL) Stock?
- Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for […]
- 07/31/2020
|
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
- Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2020
|
Gandeng Astra, Mendes optimistis kesejahteraan warga desa meningkat
- Menteri Desa Pembangunan Daerah Tertinggal dan Transmigrasi (Mendes PDTT) Abdul Halim Iskandar optimistis kelanjutan kolaborasi bersama PT Astra melalui ...
- 07/29/2020
|
Caregiver Inc. Enters a New Partnership With WindRose Health Investors
- Caregiver has entered a new partnership with WindRose Health Investors to expand into new markets and provide high-quality care to more clients.
- 07/27/2020
|
Charles River Labs International Trading In New Buy Range With Quarterly Report On Tap
- Charles River Labs International (CRL) is in a potential buy area with earnings on tap for Aug. 5. The stock is approximately 2% above a 189.95 buy point from a second-stage flat base. Understand that buying a stock just ahead of earnings involves risk since you typically don't have enough time to establish a profit cushion before the latest quarterly...
- 07/24/2020
|
How to become a data science architect?
- The experts predicted that by 2020, there will be 40 zettabytes of data in existence, and this will make career opportunities in Data Science shoot up drastically. And the shortage of skilled professionals makes Data Science a hot career opportunity for the related candidates.
- 07/23/2020
|
Begini konstruksi perkara penetapan Desi Arryani sebagai tersangka
- Komisi Pemberantasan Korupsi (KPK) menjelaskan konstruksi perkara terkait penetapan tiga tersangka dalam pengembangan kasus korupsi pelaksanaan pekerjaan ...
- 07/23/2020
|
Farallon plans to vote for the shareholder proposals at Toshiba's 181st Annual General Meeting
- Farallon Capital Management, L.L.C., on behalf of its managed funds and accounts ("Farallon"), today announced that it plans to vote for the shareholder proposals to Toshiba Corporation (Code: 6502) ("Toshiba") at Toshiba's 181st Annual General Meeting (Proposal No. 3 and No.4) (the "Shareholder Proposals").
- 07/22/2020
|
Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?
- Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/20/2020
|
IBD Stock Of The Day: Why This Medical Player Isn't Sweating The Pandemic
- Charles River Labs is the IBD Stock Of The Day after the medical testing company broke out to a record high on bullish expectations for 2020. Shares cleared an entry out of a flat base.
- 07/15/2020
|
Doncaster Sheffield Airport chaos after plane skids off runway - planes diverted
- DONCASTER Sheffield Airport has been hit by chaos this afternoon after a plane skidded off the runway into the grass, grounding all flights.
- 07/14/2020
|
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
- Charles River Laboratories schedules second-quarter 2020 earnings release and conference call
- 07/14/2020
|
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
- Charles River Laboratories schedules second-quarter 2020 earnings release and conference call
- 07/14/2020
|
Today’s AI productization challenges demand domain specific architectures
- The AI inference industry is expected to soon surpass training revenues -- moving from an AI model to a production-ready AI application.
- 07/13/2020
|
Did Hedge Funds Make The Right Call On Charles River Laboratories International Inc. (CRL) ?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/13/2020
|
The R.I.P. Portfolio's Q2 2020 Update
- This real-money portfolio was first introduced to the Seeking Alpha community in December 2015. The portfolio underperformed its benchmark in Q2 2020 and it is lagging the S&P 500's performance since late 2015.
- 07/13/2020
|
The Charles River Laboratories International (NYSE:CRL) Share Price Is Up 147% And Shareholders Are Boasting About It
- The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- 07/09/2020
|
Global Pyrogen Testing Market Outlook 2020-2027 with COVID-19 Impact Estimates - ResearchAndMarkets.com
|
The Top Data Science And Analytics Associations
- A professional association’s approach is to lead the growth, sharing and implementation of expertise in any given field. For data science and analytics, such associations support the implementation of basic, applied research and technologies in the fields of decision making, management and analytics. Professional data science associations, apart from being a body that assists in…
- 07/07/2020
|
Dr. Carl Craig Has Been Promoted to CEO for Both Agricor Laboratories and Botanacor Laboratories. Dr. Craig Had Been the Companies’ COO.
- Dr. Carl Craig Has Been Promoted to CEO for Both Agricor Laboratories and Botanacor Laboratories. Dr. Craig Had Been the Companies’ COO.
- 07/06/2020
|
Europe throws new rule book at Google, tech giants to loosen market grip
- EU’s new regulations could become a template for governments around the world looking to rein in Google, Apple, Amazon and Facebook
- 07/02/2020
|
European Digital Strategy and the Global Race for Digital Sovereignty
- “Data has become a matter of geopolitics and geoeconomics”
- 07/02/2020
|
New EU Antitrust Rules Target Google | PYMNTS.com
- The European Union (EU) has leveled new rules against Google, including regulations on data sharing and the operation of digital marketplaces.
- 07/01/2020
|
Novas regras da UE miram Google e outras gigantes da tecnologia
- A União Europeia, irritada com o fracasso em reduzir o domínio de mercado do Google, apesar de ter aplicado mais de 8 bilhões de dólares em multas, está planejando novas regras para equilibrar as condições de concorrência.
- 07/01/2020
|
EU throws new rule book at Google, tech giants in competition search
- Exasperated by its failure to loosen Google's market grip, despite more than $8 billion in fines, the European Union is lining up new rules to level the playing field for rivals.
- 07/01/2020
|
EU throws new rule book at Google, tech giants in competition search | MarketScreener
|
EU throws new rule book at Google, tech giants in competition search
- Exasperated by its failure to loosen Google's market grip, despite more than $8 billion in fines, the European Union is lining up new rules to level the playing field for rivals.
- 07/01/2020
|
EU throws new rule book at Google, tech giants in competition search
- Exasperated by its failure to loosen Google's market grip, despite more than $8 billion in fines, the European Union is lining up new rules to level the playing field for rivals.
- 07/01/2020
|
EU throws new rule book at Google, tech giants in competition search
- Exasperated by its failure to loosen Google's market grip, despite more than $8 billion in fines, the European Union is lining up new rules to level the playing field for rivals.
- 07/01/2020
|
Wizz Air : Jetting Off from Doncaster Sheffield Airport | MarketScreener
|
EU throws new rule book at Google, tech giants in competition search
- EU throws new rule book at Google, tech giants in competition search
- 07/01/2020
|
Doncaster Sheffield Airport reopens to passengers after lockdown
- Airlines Wizz Air and Aer Lingus announce they will be resuming flights from Yorkshire airports
- 06/30/2020
|
Devon photographers with Down's Syndrome reach competition finals
- The contest will be judged by one of Strictly Come Dancing's professional dancers
- 06/30/2020
|
Hundreds of Occupy City Hall protesters demand NYPD cut budget by $1bn
- Growing number of activists camp out at City Hall Park in New York City ahead of budget deadline to ask for funds to be reallocated
- 06/30/2020
|
Analysis of the COVID-19 Impact: Humanized Mouse Model Market 2020-2024 | Focus on Preventing the Spread of Pandemics to Augment Growth | Technavio
- The Global Humanized Mouse Model Market will grow by USD 74.72 mn during 2020-2024
- 06/30/2020
|
Big Pharma’s U-Turn Threatens 450-Million-Year-Old Species On Front Line Of Coronavirus Defense
- The US industry body of big pharma made a dramatic u-turn amid the coronavirus outbreak, putting at risk a 450 million-year-old species on the front lines of our Covid-19 defenses.
- 06/28/2020
|
A progressive wave in New York’s Democratic primaries — for now
- Progressives made more gains in this week’s Democratic primaries — mainly by taking out incumbents who’ve been around long enough to see the district change beneath them. Rep. Alexandria Ocasio-Cor…
- 06/27/2020
|
Legal teams discover their inner geek
- Lawyers who merge business, law and technology are redefining corporate legal departments. Plus: five general counsel who stand out for developing new products
- 06/26/2020
|
A gaming setup moonlighting as an office setup [Setups] | Cult of Mac
- YouTuber Jared Busch is a tech reviewer so when it comes to desk setups, he doesn't mess around. Most of his gear is for gaming -- and for making tech
- 06/25/2020
|
GAFA: des députés français veulent créer des règles de la concurrence spécifiques
- Daniel Fasquelle (LR) et Valéria Faure-Muntian (LaREM) veulent aller plus loin que ce que propose Bruxelles pour lutter contre les monopoles du numérique.
- 06/24/2020
|
NYC Board of Elections ‘hopes’ polling sites will be up and running tomorrow
- This primary rides on ‘hope’! A top official with the New York City Board of Elections said the agency is struggling to find ways to get enough workers to polling sites in time to open …
- 06/23/2020
|
Global Healthcare Analytical Testing Services Market (2020 to 2024) - Featuring Charles River Laboratories, Envigo & Eurofins Scientific Among Others - ResearchAndMarkets.com
|
Security Challenges: FG set to acquire space technology assets — Defence Minister
- The Federal Government said at the weekend that it has set machinery in motion for the acquisition of more Space Science...
- 06/20/2020
|
Charles River Laboratories Intl. Inc (NYSE:CRL) Stock Holdings Lifted by Legal & General Group Plc
- Legal & General Group Plc raised its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 7.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,492 shares of the medical research company’s stock after purchasing an additional 5,379 shares during […]
- 06/20/2020
|
Alliancebernstein L.P. Sells 3,800 Shares of Charles River Laboratories Intl. Inc (NYSE:CRL)
- Alliancebernstein L.P. lessened its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 4.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,140 shares of the medical research company’s stock after selling 3,800 shares during the quarter. Alliancebernstein L.P. owned approximately […]
- 06/20/2020
|
COVID 19: Debt Service Suspension Initiative
|
Jefferies Financial Group Brokers Decrease Earnings Estimates for Charles River Laboratories Intl. Inc (NYSE:CRL)
- Charles River Laboratories Intl. Inc (NYSE:CRL) – Equities research analysts at Jefferies Financial Group cut their Q2 2020 earnings estimates for shares of Charles River Laboratories Intl. in a research report issued to clients and investors on Thursday, June 18th. Jefferies Financial Group analyst D. Windley now anticipates that the medical research company will post […]
- 06/19/2020
|
Deep Dive: Adapting programmatic strategies for the new normal - Digiday
- More than anything else, the second quarter of 2020 has been dominated by uncertainty. Adjusting to this new normal, however long it lasts, isn’t going to be easy. Brands, agencies, and publishers are juggling a lot today, with diminishing resources and limited understanding on how the future will shake out.
- 06/18/2020
|
Why Apprenticeships Are The Best Way To Learn Data Skills
- American companies need new strategies for talent acquisition in data science and analytics.
- 06/18/2020
|
2:00PM Water Cooler 6/16/2020 | naked capitalism
- COVID-19 by regions (plus New York) ~ Biden veepstakes (Abrams, Bottoms, Demings, Harris, (Susan) Rice, Warren) ~ Chait gets something partially right ~ Retail, manufacturing, debt ~ PG&E "mass killing" ~ Dexamethasone ~ Masks ~ Albuquerque shooting ~ Case-Deaton on COVID ~ Github
- 06/16/2020
|
Size of Global Pyrogen Testing Market Expected to Reach USD 1,824.5 Million by 2026: Facts & Factors
- Global Pyrogen Testing market is expected to grow at a CAGR of around 12.5% and is anticipated to reach around USD 1,824.5 Million by 2026.
- 06/16/2020
|
Qiming, IDG Capital Co-Led $155M Round In Chinese AI Chip Firm Biren Technology
- Qiming, IDG Capital Co-Led $155M Round In Chinese AI Chip Firm Biren Technology – China Money Network - China Money Network
- 06/16/2020
|
Victory Capital Management Inc. Grows Position in Charles River Laboratories Intl. Inc (NYSE:CRL)
- Victory Capital Management Inc. boosted its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 164.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 94,178 shares of the medical research company’s stock after buying an additional 58,577 shares during the quarter. Victory Capital Management Inc.’s holdings in Charles River Laboratories Intl. were worth […]
- 06/16/2020
|
Sydney Harbour Bridge's last toll booths to be removed
- Removal of the booths will cost $20 million and cause 18 months of disruption to motorists on the bridge.
- 06/15/2020
|
Short Interest in Charles River Laboratories Intl. Inc (NYSE:CRL) Rises By 7.3%
- Charles River Laboratories Intl. Inc (NYSE:CRL) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totalling 1,180,000 shares, a growth of 7.3% from the May 14th total of 1,100,000 shares. Currently, 2.4% of the shares of the company are short sold. […]
- 06/15/2020
|
Charles River Laboratories Intl. (NYSE:CRL) Rating Lowered to Hold at Zacks Investment Research
- Charles River Laboratories Intl. (NYSE:CRL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe […]
- 06/14/2020
|
A closed highway and a 'mad dash' to e-commerce: Here's how one New Jersey Main St. is preparing to reopen
- Here's how business owners and local officials in Somerville, New Jersey are preparing to reopen as the state's coronavirus restrictions ease.
- 06/13/2020
|
Protein Sequencing Market 2020 | Latest Growth, Industry Analysis, Strategies of Key Players: …. | Value Market Research
- Jun 12, 2020 (CDN Newswire via Comtex) --
The global Protein Sequencing Market report gives a segmentation by product & service, technology, application,...
- 06/12/2020
|
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
- Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
- 06/11/2020
|
Moving Average Crossover Alert: Charles River Laboratories International
- Charles River Laboratories International, Inc. (CRL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 06/11/2020
|
‘I didn’t think I could go to university and now my dream is to graduate by 40’
- A degree with The Open University is accessible to all
- 06/11/2020
|
‘I didn’t think I could go to university and now my dream is to graduate by 40’
- A degree with The Open University is accessible to all
- 06/11/2020
|
4 GARP Stocks to Scoop Up for Maximum Returns
- If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
- 06/10/2020
|
JPMorgan Chase & Co. Increases Stock Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)
- JPMorgan Chase & Co. lifted its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 14.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,548 shares of the medical research company’s stock after buying an additional 12,607 shares […]
- 06/10/2020
|
Uptrend Call Working As Charles River La Stock Rises 55.1% (CRL)
- Jun 08, 2020 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend identified an Uptrend for Charles River La (NYSE:CRL) on March 25th, 2020 at $115.66. In...
- 06/08/2020
|
10 Reasons why Hot Forex is Nigeria’s most used Forex Trading Platform - Businessday NG
- Hot Forex is a highly reputable broker that was founded in 2010 and has local offices along with support in Nigeria. Apart from this, Hot Forex has a global
- 06/06/2020
|
EU Policy Paper Calls for “European Internet” that Can, “Like the Chinese Firewall”, Block Services
- “An action plan for a digital cloud”
- 06/05/2020
|
Left-wing mayhem
- Understanding the anarchists, antifa activists, and other radicals trying to hijack the George Floyd protests.
- 06/05/2020
|
Data Scientist is better than Financial Analyst, Data Analyst and Research Analyst
- Though there are many options to take your pick from, most aspirants have their eyes fixated on the coveted job of data scientists.
- 06/04/2020
|
We Need to Understand Why Riots are Happening. Here’s What People Who Were There Observed.
- Civil disobedience must continue until system wide changes are made, in your city, and in the entire country
- 06/04/2020
|
Antifa, Other Far-Left Groups Exploit Protests for ‘Revolution’
- Communist groups—including the extremist organization Antifa—are hijacking what started out as peaceful protests over the death of an ...
- 06/03/2020
|
Firefox fixes cryptographic data leakage in latest security update
- How time flies – the latest four-weekly Firefox update is out.
- 06/03/2020
|
Stocks That Hit 52-Week Highs On Wednesday
|
Hedge Funds Never Been This Bullish On Charles River Laboratories International (CRL)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/03/2020
|
Stocks That Hit 52-Week Highs On Tuesday
|
Hedge Funds Never Been This Bullish On Charles River Laboratories International (CRL)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/02/2020
|
Edited Transcript of CRL earnings conference call or presentation 7-May-20 1:30pm GMT
- Q1 2020 Charles River Laboratories International Inc Earnings Call
- 06/02/2020
|
HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
- HemaCare, a Charles River company, announced that it has expanded its portfolio with the launch of the GMPrime cryopreserved leukopak.
- 06/02/2020
|
Charles River Laboratories' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Charles River Laboratories.
- 06/02/2020
|
Wildlife groups pressure Big Pharma to curb crab blood addiction | MarketScreener
|
Wildlife groups pressure Big Pharma to curb crab blood addiction
- By John MillerZURICH, June 1 (Reuters) - Wildlife advocates are pushing drugmakers to curb the use of horseshoe crab blood by switching to a synthetic...
- 06/01/2020
|
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
- Charles River Laboratories to participate in Jefferies and William Blair Conferences
- 06/01/2020
|
Drug Discovery Informatics Market Analysis as per the Latest COVID-19 Impact
- Jun 01, 2020 (Heraldkeepers) --
New York, June 01, 2020: Market Research Engine has published a new report titled as "Drug Discovery Informatics Market Size...
- 06/01/2020
|
Biopharmaceutical Analytical Testing Services Market 2020-2024 | Increase in Number of Patent-Expired Drugs to Boost Growth | Technavio
- The Global Biopharmaceutical Analytical Testing Services Market will grow by USD 1.18 bn during 2020-2024
- 06/01/2020
|
Cities Burn, but None Dare Call It Communist Insurrection
- Commentary In the past few days, several cities have seen chaotic rioting. Cars and buildings have been torched, ...
- 05/31/2020
|
Drugs standards group nixes plan to kick pharma's crab blood habit
- Horseshoe crabs' icy-blue blood will remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to give equal status to a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
- 05/31/2020
|
Omar's daughter retweets socialist account pleading for help supplying Floyd rioters
- Rep. Ilhan Omar’s daughter appeared to express support for rioters in Minneapolis following the controversial death of a black man while in police custody.
- 05/30/2020
|
Drugs standards group nixes plan to kick pharma's crab blood habit
- Horseshoe crabs' icy-blue blood is set to remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to put on an equal footing a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
- 05/30/2020
|
IAF chief exclusive: Rafales arriving July-end; Air Force prepared to counter any threat including two-front war
- While preparations are on to receive the French combat aircraft Rafale end of July, the Indian Air Force (IAF) is keen to induct platforms, weapons & systems made here in India.
- 05/28/2020
|
Li & Fung Delists After Completing HK$7.2B GLP-Led Buyout
- Consumer goods sourcing and distribution firm Li & Fung delisted from the Hong Kong stock
- 05/28/2020
|
Shinshu University and Toshiba Develop Tumor-Tropic Liposome Technology that Carries Therapeutic Genes into Cancer Cells
- Toshiba Corporation (TOKYO: 6502, hereinafter "Toshiba") and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, (hereinafter "Shinshu University"), have together developed a "tumor-tropic liposome technology" for gene therapy*1. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
- 05/28/2020
|
COVID-19 Impact: A Mix of Challenges and Opportunities | Humanized Mouse Model Market 2020-2024 | Rising Focus On Preventing The Spread Of Pandemics to Boost Growth | Technavio
- The humanized mouse model market size has the potential to grow by USD 74.72 million during 2020-2024
- 05/27/2020
|
Global Patient Derived Xenograft or PDX Models Market 2020 Research Report Insights and Analysis, Forecast to 2026
- May 26, 2020 (Market Insight Reports) --
The Patient Derived Xenograft or PDX Models market has witnessed growth from USD XX million to USD XX million from...
- 05/26/2020
|
Rat Model Market by Size, Growth, Opportunity and Forecast to 2025
- May 26, 2020 (Market Insight Reports) --
Selbyville, Delaware the newly Added research report at Market Study Report titled "2019-2025 Global Rat Model...
- 05/26/2020
|
JPMC Interview Experience
- Sharing my Interview Experience for JPMorganChase as software intern.
- 05/23/2020
|
Waspada kelola utang di masa pandemi COVID-19
- Badan Pemeriksa Keuangan (BPK) telah menyampaikan Ikhtisar Hasil Pemeriksaan Semester (IHPS) Semester II-2019 kepada lembaga perwakilan dan ...
- 05/23/2020
|
A Rising Share Price Has Us Looking Closely At Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Ratio
- Charles River Laboratories International (NYSE:CRL) shares have had a really impressive month, gaining 30%, after some...
- 05/21/2020
|
Charles River Laboratories International Inc (CRL) Chairman, President and CEO James C Foster ...
|
Centivax Antibodies Neutralize the Pandemic Coronavirus, Independently Confirmed by Three Research Laboratories (USAMRIID, Stanford, and UTMB/GNL)
- Centivax Inc, the therapeutics spin-out of Contract Research Organization Distributed Bio Inc, announced a significant advance in their mission to develop an...
- 05/18/2020
|
New Post From Your Neighbor
- Can people travel in and out of NYC at this time?
- 05/18/2020
|
How the direct selling business model empowers budding entrepreneurs
- Direct selling has proven successful in combating unemployment as more than one in every three young people of working age in South Africa did not have a job this year.
- 05/18/2020
|
Shanda Payment Holdings Ltd. Buys Alphabet Inc, Lockheed Martin Corp, BlackRock Inc, Sells ...
|
Global Partners: High Leverage Points To Further Distribution Cuts
- Global Partners reduced its distribution by 25% several weeks ago, which has become commonplace across the market with near countless peers taking this same act
- 05/14/2020
|
Thousands of Americans Have Become Socialists Since March
- The Democratic Socialists of America have an estimated 10,000 new members—growth that organizers attribute, in part, to the coronavirus pandemic.
- 05/14/2020
|
Benzinga's Top Upgrades, Downgrades For May 13, 2020
|
Charles River Labs: The Short-Term Headwinds Will Eventually Be Long-Term Tailwinds
- Charles River reported Q1 2020 results that beat the top- and bottom-line estimates. The COVID-19 related headwinds will impact Charles River's results over the
- 05/13/2020
|
UBS Upgrades Charles River to Buy, Raises Price Target of $200
|
Charles River Laboratories International Inc (CRL) Chairman, President and CEO James C Foster ...
|
Deutsche Bank Maintains Buy on Charles River, Lowers Price Target to $174
|
DSA exercise begins with selection process going online
- Application for entry to secondary schools and junior colleges next year through the Direct School Admission (DSA) exercise will open from today, with the selection process moving online in the light of the Covid-19 situation.. Read more at straitstimes.com.
- 05/11/2020
|
Coronavirus: Direct School Admission exercise to open on May 12, with selection process going virtual
- A total of 146 secondary schools and 20 junior colleges are participating this year in DSA.. Read more at straitstimes.com.
- 05/11/2020
|
At US$160, Is It Time To Put Charles River Laboratories International, Inc. (NYSE:CRL) On Your Watch List?
- Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in...
- 05/09/2020
|
JP Morgan Maintains Overweight on Charles River, Raises Price Target to $180
|
SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to $194
|
Credit Suisse Maintains Neutral on Charles River, Lowers Price Target to $159
|
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $175
|
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
- Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Computer Programs and Systems Inc : Cantor Fitzgerald raises to overweight from neutral
* Epam Systems Inc : Citigroup raises price target to $265 from $245
* PayPal Holdings Inc : Citigroup raises price target to $145 from $131
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical
order.
* Aaron's Inc : Keybanc cuts target price to $55 from $66
* Aaron's Inc : Raymond James cuts target price to $50 from $60
* Aaron's Inc : Stephens raises target price to $45 from $26
* Abeona Therapeutics Inc : RBC cuts target price to $7 from $11
* Acceleron pharma Inc : Credit Suisse raises target price to $123 from $99
* ACI Worldwide Inc : Canaccord Genuity cuts target price to $35 from $44
* Acushnet Holdings Corp : Jefferies raises target price to $25 from $24
* Acushnet Holdings Corp : JP Morgan raises target price to $30 from $27
* Adtran Inc : Cowen and Company raises price target to $13 from $9
* Aeglea Bio Therapeutics Inc : Needham cuts price target to $11 from $14
* Aerie Pharmaceuticals Inc : Citigroup cuts price target to $38 from $39
* Agco Corp : Citigroup cuts price target to $55 from $57
* AIG : KBW raises target price to $36 from $35
* Alaska Air Group Inc : Credit Suisse cuts target price to $51 from $82
* Allison Transmission Holdings Inc : Citigroup raises price target to $39 from $38
* Allscripts Healthcare Solutions : Cantor Fitzgerald cuts PT to $6 from $8
* Alteryx Inc : Guggenheim cuts target price to $130 from $160
* American Airlines : Credit Suisse cuts target price to $4 from $26
* Ameriprise Financial Inc : Credit Suisse raises target price to $165 from $153
* Ameriprise Financial Inc : Piper Sandler raises target price to $150 from $130
* Amerisourcebergen Corp : Baird raises target price to $115 from $109
* Amerisourcebergen Corp : Mizuho raises target price to $90 from $85
* Amtech Systems Inc : Cowen and Company raises target price to $7.50 from $7
* Angi Homeservices Inc : Needham raises target price to $11 from $8
* Ani Pharmaceuticals Inc : Guggenheim cuts target price to $48 from $58
* Ansys Inc : RBC raises target price to $260 from $230
* Anthem Inc : Bernstein raises target price to $357 from $342
* Appian Corp : Cowen and Company raises price target to $44 from $39
* Applied Optoelectronics Inc : D.A. Davidson raises target price to $12 from $10
* Applied Optoelectronics Inc : Piper Sandler raises target price to $10 from $7.50
* Aptiv Plc : Citigroup raises price target to $84 from $67
* ArcelorMittal SA : Keybanc raises target price to $15 from $13
* Arcturus Therapeutics Holdings Inc : Baird raises target price to $44 from $26
* Arcturus Therapeutics Holdings Inc : Guggenheim raises target price to $51 from $41
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Athersys Inc : Needham cuts price target to $5 from $6
* Atlas Air Worldwide Holdings Inc : Cowen and Company raises PT to $44 from $40
* Avalara Inc : Canaccord Genuity raises target price to $115 from $105
* Avalara Inc : JP Morgan raises target price to $120 from $104
* Avalara Inc : Mizuho raises price target to $120 from $85
* Avalara Inc : Piper Sandler raises target price to $113 from $90
* Avalonbay Communities Inc : Stifel raises target price to $176 from $171
* Avrobio Inc : Guggenheim raises target price to $50 from $49
* Axalta Coating Systems Ltd : RBC raises target price to $21 from $20
* Bausch Health Companies Inc : Piper Sandler cuts target price to $32 from $34
* Beacon Roofing Supply Inc : SunTrust Robinson raises target price to $26 from $24
* Beacon Roofing Supply Inc : Wedbush raises target price to $23 from $16
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Becton Dickinson and Co : Evercore ISI raises target price to $270 from $255
* Beyond Meat Inc : Berenberg raises price target to $125 from $115
* Bill.Com Holdings Inc : Canaccord Genuity raises target price to $65 from $50
* Bill.Com Holdings Inc : Jefferies raises target price to $70 from $45
* Bill.Com Holdings Inc : Keybanc raises target price to $76 from $60
* Bill.Com Holdings Inc : Needham raises target price to $90 from $55
* Biomarin Pharmaceutical Inc : Canaccord Genuity raises PT to $119 from $108
* BJ's Restaurants Inc : Wedbush cuts target price to $32 from $39
* Booking Holdings Inc : Credit Suisse raises target price to $1,810 from $1,790
* Booking Holdings Inc : Jefferies cuts target price to $1300 from $1350
* Booking Holdings Inc : Mizuho cuts price target to $1700 from $1720
* Booking Holdings Inc : RBC raises target price to $1,550 from $1,535
* Booking Holdings Inc : RBC raises target price to $1550 from $1535
* BorgWarner Inc : Citigroup raises price target to $30 from $23
* BorgWarner Inc : Credit Suisse raises target price to $33 from $31
* Bottomline Technologies (De) Inc : Citigroup raises price target to $46 from $43
* Bright Horizons Family Solutions Inc : Citigroup raises PT to $122 from $80
* Brightsphere Investment Group Inc : Evercore ISI raises target to $9 from $6
* Brightsphere Investment Group Inc : KBW raises target price to $9.50 from $7.25
* Brightview Holdings Inc : Credit Suisse cuts target price to $14 from $18
* Brightview Holdings Inc : Jefferies raises target price to $14 from $12
* Cabot Microelectronics Corp : Citigroup cuts price target to $140 from $175
* Cactus Inc : zephirin Group raises price objective to $12 from $8
* Calithera Biosciences Inc : Jefferies raises target price to $9 from $6
* Calyxt Inc : BMO cuts price target to $7 from $13
* Calyxt Inc : BMO cuts to market perform from outperform
* Camping World Holdings Inc : Credit Suisse raises target price to $12 from $11
* Camping World Holdings Inc : JP Morgan raises price target to $11 from $10
* Capstar Financial Holdings Inc : KBW raises target price to $11 from $10.50
* Cargurus Inc : BTIG raises target price to $26 from $23
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Castlight Health Inc : Cantor Fitzgerald cuts target price to $1 from $2
* Catasys Inc : Canaccord Genuity raises target price to $36 from $35
* CBRE Group Inc : Evercore ISI cuts target price to $48 from $50
* CBRE Group Inc : KBW cuts target price to $51 from $52
* Centerpoint Energy Inc : Guggenheim raises target price to $26 from $25
* Centerpoint Energy Inc : Keybanc raises target price to $16 from $12
* Centurylink Inc : RBC cuts target price to $10 from $14
* CF Industries Holdings Inc : Citigroup cuts price target to $29 from $31
* CF Industries Holdings Inc : Scotiabank raises target price to $32 from $31
* ChannelAdvisor Corp : Needham raises price target to $14 from $11
* Charles River Laboratories International : Credit Suisse cuts PT to $159 from $162
* Charles River Laboratories International : Evercore ISI ups PT to $176 from $154
* Charles River Laboratories International : Jefferies raises PT to $161 from $139
* Charles River Laboratories International Inc : Citigroup raises price target to $190 from $165
* Chart Industries Inc : zephirin Group raises price objective to $25 from $17
* Charter Communications Inc : Benchmark raises price target to $600 from $523
* Chemours Co : Citigroup raises price target to $13 from $8
* Cimarex Energy Co : MKM Partners raises target price to $34 from $31
* City Holding Co : Stephens cuts target price to $63 from $64.
- 05/08/2020
|
Citigroup Maintains Buy on Charles River, Raises Price Target to $190
|
How Doncaster Sheffield Airport is helping bring vital PPE to NHS heroes
- It was supposed to be a 'bumper year' of flying passengers to holiday destinations but instead DSA is helping with the fight against coronavirus
- 05/08/2020
|
Edited Transcript of CRL earnings conference call or presentation 7-May-20 1:30pm GMT
- Q1 2020 Charles River Laboratories International Inc Earnings Call
- 05/08/2020
|
Charles River Laboratories International Inc (CRL) Q1 2020 Earnings Call Transcript
- CRL earnings call for the period ending March 31, 2020.
- 05/08/2020
|
Glu Mobile: Undervalued Pandemic-Resistant Play
- Glu Mobile stock is starting to look up after a volatile year. We expect the uptrend in the stock price to continue and even accelerate. Well managed live opera
- 05/07/2020
|
Charles River Laboratories (CRL) Q1 Earnings and Revenues Surpass Estimates
- Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/07/2020
|
Charles River Laboratories Announces First-Quarter 2020 Results
- Charles River Laboratories Announces First-Quarter 2020 Results
- 05/07/2020
|
Charles River Laboratories Announces First-Quarter 2020 Results
- Charles River Laboratories Announces First-Quarter 2020 Results
- 05/07/2020
|
JP Morgan Signs Up for $600M China Logistics JV with New Ease
- Shanghai-based industrial developer New Ease has set up a joint venture with JP Morgan Asset
- 05/06/2020
|
Baring Private Equity Asia Raises $480M for China Logistics Venture
- Baring Private Equity Asia has closed a $480 million commitment to a mainland China logistics
- 05/04/2020
|
RMS Releases New High Definition Models for European Severe Convective Storm
- RMS, the leading global risk modeling and analytics firm, announced today at its annual Exceedance conference the release of new European Severe Conve
- 05/04/2020
|
Quarentena, distanciamento e lockdown: entenda a diferen
- Com base em informa
- 05/01/2020
|
SPECIAL REPORT-Trump told Saudis: Cut oil supply or lose U.S. military support - sources
- As the United States pressed Saudi Arabia to end its oil price war with Russia, President Donald Trump gave Saudi leaders an ultimatum.
- 04/30/2020
|
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
- Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
- Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
SPECIAL REPORT-Trump told Saudis: Cut oil supply or lose U.S. military support - sources
- As the United States pressed Saudi Arabia to end its oil price war with Russia, President Donald Trump gave Saudi leaders an ultimatum.
- 04/30/2020
|
Charles River Laboratories Intl. (CRL) to Release Earnings on Thursday
- Charles River Laboratories Intl. (NYSE:CRL) will be posting its quarterly earnings results before the market opens on Thursday, May 7th. Analysts expect Charles River Laboratories Intl. to post earnings of $1.48 per share for the quarter. Charles River Laboratories Intl. has set its FY 2020 Pre-Market guidance at 7.45-7.60 EPS and its FY20 guidance at […]
- 04/30/2020
|
Charles River Labs International Clears Key Benchmark, Hitting 80-Plus RS Rating
|
